Early empirical antimicrobial therapy does not prevent sepsis development in critically ill surgical patients with suspected nosocomial infection: a retrospective analysis

2020 ◽  
Author(s):  
Estêvão Bassi ◽  
Bruno Martins Tomazini ◽  
Bárbara Vieira Carneiro ◽  
Amanda Rodrigues de Oliveira Siqueira ◽  
Sara Rodrigues de Oliveira Siqueira ◽  
...  

Abstract Background: Early administration of antibiotics to septic shock patients decreases in-hospital mortality, but there is a lack of studies evaluating the role of early empirical antibiotics in surgical patients with suspected nosocomial infection without sepsis. Methods: Retrospective cohort of adult patients admitted to a surgical Intensive Care Unit in a tertiary hospital. We defined early empirical antibiotic group by the initiation of antibiotic therapy within 24h after infection’s suspicion, and conservative group by antibiotic therapy initiation 24 hours after infection’s suspicion or not prescribed within 14 days. The primary outcome was a composite of death, septic shock or sepsis within 14 days from the clinical suspicion of infection. Regression models were used to identify associations between factors and the primary outcome. Results: From 2007 patients admitted to intensive care unit, 341 surgical patients (71% trauma patients) with suspected nosocomial infection without sepsis and with no obvious source of infection were included in the cohort. Age, gender, traumatic brain injury, admission type (trauma vs. non-trauma), SAPS 3, SOFA, vasopressor use or rate of mechanical ventilation did not differ between early empirical antibiotic and conservative groups. In the conservative group, 57% of patients received antibiotics within 14 days. The composite primary outcome occurred in 41% of patients in the conservative group and 56% in the early empirical antimicrobial group, (p=0.007). The 14-day incidence of septic shock or mortality was similar in both groups. Multivariate analysis showed early antimicrobial therapy (OR 1.83 [95% CI 1.16-2.88] , p = 0.008), non-trauma admission (OR 2.32 [1.40-3.90], p = 0.001) and mechanical ventilation (OR 2.09 [1.31-3.35], p = 0.002) were associated with the primary outcome. Exploratory analysis including only patients with positive cultures also did not find any benefit of early empiric antibiotic therapy (OR 1.39 [0.78-2.49], p = 0.26) Conclusions: Early empiric antibiotic therapy does not decrease the incidence of sepsis, septic shock or death within 14 days in critically ill stable surgical patients with suspected infection but with no obvious source.

2020 ◽  
Vol 48 (12) ◽  
pp. e1370-e1371 ◽  
Author(s):  
Ruben D. Villanueva ◽  
Joseph A. Iovine ◽  
Scott G. Blair ◽  
Ryan O. Kennedy ◽  
Jasmeet S. Paul

2016 ◽  
Vol 17 (2) ◽  
pp. 210-216 ◽  
Author(s):  
Taku Oshima ◽  
Yoshiyuki Kodama ◽  
Waka Takahashi ◽  
Yosuke Hayashi ◽  
Shinya Iwase ◽  
...  

2008 ◽  
Vol 74 (6) ◽  
pp. 516-523 ◽  
Author(s):  
Louis J. Magnotti ◽  
Thomas J. Schroeppel ◽  
Timothy C. Fabian ◽  
L. Paige Clement ◽  
Joseph M. Swanson ◽  
...  

Empiric antibiotic therapy is routinely initiated for patients with presumed ventilator-associated pneumonia (VAP). Reported mortality rates for inadequate empiric antibiotic therapy (IEAT) for VAP range from 45 to 91 per cent. The purpose of this study was to determine the effect of a unit-specific pathway for the empiric management of VAP on reducing IEAT episodes and improving outcomes in trauma patients. Patients admitted with VAP over 36-months were identified and stratified by gender, age, severity of shock, and injury severity. Outcomes included number of IEAT episodes, ventilator days, intensive care unit days, hospital days, and mortality. Three hundred and ninety-three patients with 668 VAP episodes were identified. There were 144 (22%) IEAT episodes: significantly reduced compared with our previous study (39%) ( P < 0.001). Patients were classified by number of IEAT episodes: 0 (n = 271), 1 (n = 98) and ≥ 2 (n = 24). Mortality was 12 per cent, 13 per cent, and 38 per cent ( P < 0.001), respectively. Multivariable logistic regression identified multiple IEAT episodes as an independent predictor of mortality (odds ratio = 4.7; 95% confidence interval: 1.684–13.162). Multiple IEAT episodes were also associated with prolonged mechanical ventilation and intensive care unit stay ( P < 0.001). Trauma patients with multiple IEAT episodes for VAP have increased morbidity and mortality. Adherence to a unit-specific pathway for the empiric management of VAP reduces multiple IEAT episodes. By limiting IEAT episodes, resource utilization and hospital mortality are significantly decreased.


Author(s):  
Stefano Busani ◽  
Erika Roat ◽  
Giulia Serafini ◽  
Elena Mantovani ◽  
Emanuela Biagioni ◽  
...  

Patients with septic shock by multidrug resistant microorganisms (MDR) are a specific sepsis population with a high mortality risk. The exposure to an initial inappropriate empiric antibiotic therapy has been considered responsible for the increased mortality, although other factors such as immune-paralysis seem to play a pivotal role. Therefore, beyond conventional early antibiotic therapy and fluid resuscitation, this population may benefit from the use of alternative strategies aimed at supporting the immune system. In this review we present an overview of the relationship between MDR infections and immune response and focus on the rationale and the clinical data available on the possible adjunctive immunotherapies, including blood purification techniques and different pharmacological approaches.


2020 ◽  
Vol 41 (S1) ◽  
pp. s44-s45
Author(s):  
Sameer Kadri ◽  
Yi Ling Lai ◽  
Sarah Warner ◽  
Jeffrey R. Strich ◽  
Ahmed Babiker ◽  
...  

Background: Delayed or in vitro inactive empiric antibiotic therapy may be detrimental to survival in patients with bloodstream infections (BSIs). Understanding the landscape of delayed or discordant empiric antibiotic therapy (DDEAT) across different patient, pathogen, and hospital types, as well as by their baseline resistance milieu, may enable providers, antimicrobial stewardship programs, and policy makers to optimize empiric prescribing. Methods: Inpatients with clinically suspected serious infection (based on sampling of blood cultures and receiving systemic antibiotic therapy on the same or next day) found to have BSI were identified in the Cerner Healthfacts EHR database. Patients were considered to have received DDEAT when, on culture sampling day, they received either no antibiotic(s) or none that displayed in vitro activity against the pathogenic bloodstream isolate. Antibiotic-resistant phenotypes were defined by in vitro resistance to taxon-specific prototype antibiotics (eg, methicillin/oxacillin resistance in S. aureus) and were used to estimate baseline resistance prevalence encountered by the hospital. The probability of DDEAT was examined by bacterial taxon, by time of BSI onset, and by presence versus absence of antibiotic-resistance phenotypes, sepsis or septic shock, hospital type, and baseline resistance. Results: Of 26,036 assessable patients with a BSI at 131 US hospitals between 2005 and 2014, 14,658 (56%) had sepsis, 3,623 (14%) had septic shock, 5,084 (20%) had antibiotic-resistant phenotypes, and 8,593 (33%) received DDEAT. Also, 4,428 (52%) recipients of DDEAT received no antibiotics on culture sampling day, whereas the remaining 4,165 (48%) received in vitro discordant therapy. DDEAT occurred most often in S. maltophilia (87%) and E. faecium (80%) BSIs; however, 75% of DDEAT cases and 76% of deaths among recipients of DDEAT collectively occurred among patients with S. aureus and Enterobacteriales BSIs. For every 8 bacteremic patients presenting with septic shock, 1 patient did not receive any antibiotics on culture day (Fig. 1A). Patients with BSIs of hospital (vs community) onset were twice as likely to receive no antibiotics on culture day, whereas those with bloodstream pathogens displaying antibiotic-resistant (vs susceptible) phenotypes were 3 times as likely to receive in vitro discordant therapy (Fig. 1B). The median proportion of DDEAT ranged between 25% (14, 37%) in eight <300-bed teaching hospitals in the lowest baseline resistance quartile and 40% (31, 50%) at five ≥300-bed teaching hospitals in the third baseline resistance quartile (Fig. 2). Conclusions: Delayed or in vitro discordant empiric antibiotic therapy is common among patients with BSI in US hospitals regardless of hospital size, teaching status, or local resistance patterns. Prompt empiric antibiotic therapy in septic shock and hospital-onset BSI needs more support. Reliable detection of S. aureus and Enterobacteriales bloodstream pathogens and their resistance patterns earlier with rapid point-of-care diagnostics may mitigate the population-level impact of DDEAT in BSI.Funding: This study was funded in part by the National Institutes of Health Clinical Center, National Institutes of Allergy and Infectious Diseases, National Cancer Institute (NCI contract no. HHSN261200800001E) and the Agency for Healthcare Research and Quality.Disclosures: None


2015 ◽  
Vol 63 (S 01) ◽  
Author(s):  
C. Schimmer ◽  
K. Hamouda ◽  
M. Oezkur ◽  
S. Sommer ◽  
M. Leistner ◽  
...  

Antibiotics ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 250
Author(s):  
Yong Chan Kim ◽  
Jung Ho Kim ◽  
Jin Young Ahn ◽  
Su Jin Jeong ◽  
Nam Su Ku ◽  
...  

Implementation of antibiotic stewardship is difficult in patients with sepsis because of severity of disease. We evaluated the impact of glycopeptide discontinuation (GD) in patients with culture negative severe sepsis or septic shock who received glycopeptides as initial empiric antibiotic therapy at admission. We conducted a single center retrospective cohort study between January 2010 and March 2018. GD was defined as discontinuation of initial empiric glycopeptides on availability of culture results, revealing the absence of identified pathogens. In 92 included patients, the leading causes of sepsis were pneumonia (34.8%) and intra-abdominal infection (23.9%); 28-day mortality and overall mortality were 14% and 21%, respectively. Glycopeptides were discontinued in 42/92 patients. After propensity score matching, baseline characteristics were not significantly different between the GD and non-GD (GND) groups. GND was associated with development of acute kidney injury (OR 5.54, 95% CI 1.49–20.6, P = 0.011). GD did not increase the 7-day, 14-day, and 28-day mortality compared with GND. The length of hospital stay was shorter in the GD group than in GND group (16.33 ± 17.11 vs. 25.05 ± 14.37, P = 0.082), though not statistically significant. GD may be safe and reduce adverse events of prolonged antibiotic use in patients with culture negative severe sepsis or septic shock receiving glycopeptides as initial empiric antibiotic therapy.


2017 ◽  
Vol 96 (1) ◽  
pp. 23-28 ◽  
Author(s):  
K.B. Pouwels ◽  
E. Van Kleef ◽  
S. Vansteelandt ◽  
R. Batra ◽  
J.D. Edgeworth ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document